Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Riminophenazines with 2-(heteroaryl)amino substituents and their anti-microbial activity

A technology of substituents and cycloalkylamino groups, applied in the field of treatment of Mycobacterium tuberculosis and other microbial infections, can solve the problems of skin discoloration, high fat tissue distribution, long half-life and the like

Active Publication Date: 2013-04-03
北京协和制药二厂有限公司 +1
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The main disadvantages of clofazimine are skin discoloration, high adipose tissue distribution and very long half-life (70 days)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Riminophenazines with 2-(heteroaryl)amino substituents and their anti-microbial activity
  • Riminophenazines with 2-(heteroaryl)amino substituents and their anti-microbial activity
  • Riminophenazines with 2-(heteroaryl)amino substituents and their anti-microbial activity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1 1

[0079] Embodiment 1. General synthetic method

[0080] The following provides the preparation of 5-(4-chlorophenyl)-3-(1-methylethyl)imino-2-(3-pyridyl)amino-3,5-dihydrophenazine (TBI-416) Or a general method for the clofazine compounds of the invention.

[0081] Step A: 2-(4-Chloroanilino)-nitrobenzene

[0082] A mixture of 2-fluoro-nitrobenzene (33.7 g), 4-chloroaniline (61.0 g) and anhydrous potassium fluoride (13.9 g) was stirred at 180° C. for 10 hours. After cooling to room temperature, 3M HCl was added and the mixture was stirred at 100°C for 30 minutes. It was then cooled to room temperature, filtered by suction and washed with water to give a brown solid. Dissolve the solid in CH 2 Cl 2 medium, and filtered through a thin pad of silica gel, with CH 2 Cl 2 washing. The filtrate was concentrated to dryness, and the residue was recrystallized from 95% ethanol to give 57.0 g of an orange solid.

[0083] Step B: 2-(4-Chloroanilino)-aniline

[0084] To the CH of 2...

Embodiment 2

[0124] Example 2 In Vitro Determination of Antimicrobial Susceptibility

[0125] Antimicrobial susceptibility testing was performed in 96-well plates. Initial drug dilutions (6.4 mg / ml) were prepared in dimethylsulfoxide followed by two-fold dilutions in 0.1 ml of 7H9 in microplates. The final drug concentration was about 0.008 μg / ml. Each concentration of test compound was added to two wells. Control wells consisted of bacteria and positive drug (clofazimine). Plates were incubated at 37°C. The final bacterial titer was for H 37 Rv 1 x 10 6 CFU / ml. From day 7 of incubation, add 20 μl of 10× Alamar blue solution and 12.5 μl of 20% Tween 80 to each well and re-incubate the plate at 37 °C. Wells were observed at 24 hours and the color of all wells was recorded. The visual MIC (visual MIC) was defined as the lowest amount of drug that prevented the color from blue to pink. Fluorescence was measured in a microplate fluorometer in bottom reading mode with excitation at 530...

Embodiment 3

[0126] Example 3 in vivo test

[0127] Use 0.2ml containing 1×10 5 CFU of H 37 The dose of RV was used to infect male BALB / c mice (18-20 g) intravenously. One day after infection, four mice were sacrificed and the number of CFU in spleen and lung was determined. Organs were removed and homogenized in Middlebrook 7H9 medium. To calculate CFU, appropriate dilutions of the homogenate were plated onto Middlebrook 7H10 agar and colony counts were performed after incubation at 37°C for 3 to 4 weeks. The remaining mice were assigned to untreated or multiple drug-treated groups (six mice per group). The dose of each test compound was 20 mg / kg. The positive control group was treated with isoniazid and clofazimine. Test compounds and clofazimine were administered 5 times per week by gavage. CMC was administered to untreated mice by gavage. 30 days after infection, untreated and treated mice were sacrificed to determine the CFU count in lung tissue. Significance of differences i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to riminophenazines having heteroaromatic substitutions, including those with 2-heteroaryl-amino substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.

Description

[0001] related application [0002] This application claims priority to US Provisional Patent Application No. 61 / 359,638, filed June 29, 2010, the entire contents of which are incorporated herein by reference. Background technique [0003] The present invention relates to riminophenazines with heteroaromatic substituents, their preparation and their use as medicaments alone or in combination with other anti-infective therapeutic agents for the treatment of Mycobacterium tuberculosis and other microbial infections use. [0004] Mycobacterium tuberculosis ("M.tb") is the causative agent of the devastating infectious disease tuberculosis ("TB"). It is estimated that about two million TB patients die each year worldwide. New drugs are urgently needed to combat the growing tuberculosis threat. [0005] Current first-line drug therapy for tuberculosis is long and complex, involving the daily delivery of a multidrug combination (usually isoniazid, rifampicin, pyrazinamide, and eth...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D401/12A61P31/06A61K31/495
CPCC07D401/14C07D403/12A61K31/498C07D407/14A61K31/506C07D409/12C07D405/12C07D401/12A61K31/5377C07D409/14A61K45/06C09B55/009C09B17/00A61P31/04A61P31/06
Inventor 刘凯克里斯多佛·B·库珀黄海洪李春刘宾娜刘洋马振坤王景斌尹大利张东峰张刚张浩
Owner 北京协和制药二厂有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com